Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Geneos Wealth Management Inc. decreased its position in Sanofi (NASDAQ:SNY – Free Report) by 2.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,223 shares of the company’s stock ...

Fifth Third Bancorp reduced its stake in Sanofi (NASDAQ:SNY – Free Report) by 9.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange ...

BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year.

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

DelveInsight's“Bullous Pemphigoid Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bullous Pemphigoid, historical and forecasted epidemiology as ...

If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition ...